JP2023500409A5 - - Google Patents
Info
- Publication number
- JP2023500409A5 JP2023500409A5 JP2022527088A JP2022527088A JP2023500409A5 JP 2023500409 A5 JP2023500409 A5 JP 2023500409A5 JP 2022527088 A JP2022527088 A JP 2022527088A JP 2022527088 A JP2022527088 A JP 2022527088A JP 2023500409 A5 JP2023500409 A5 JP 2023500409A5
- Authority
- JP
- Japan
- Prior art keywords
- composition
- antibody
- use according
- fragment
- seq
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962934078P | 2019-11-12 | 2019-11-12 | |
| US62/934,078 | 2019-11-12 | ||
| PCT/US2020/060309 WO2021097146A1 (en) | 2019-11-12 | 2020-11-12 | Methods and compositions for treating cancer |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2023500409A JP2023500409A (ja) | 2023-01-05 |
| JP2023500409A5 true JP2023500409A5 (cg-RX-API-DMAC10.html) | 2023-11-17 |
| JP7722989B2 JP7722989B2 (ja) | 2025-08-13 |
Family
ID=75912868
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022527088A Active JP7722989B2 (ja) | 2019-11-12 | 2020-11-12 | がんを治療するための方法及び組成物 |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US12570731B2 (cg-RX-API-DMAC10.html) |
| EP (1) | EP4058042A4 (cg-RX-API-DMAC10.html) |
| JP (1) | JP7722989B2 (cg-RX-API-DMAC10.html) |
| KR (1) | KR20220131222A (cg-RX-API-DMAC10.html) |
| CN (1) | CN115003319B (cg-RX-API-DMAC10.html) |
| CA (1) | CA3160636A1 (cg-RX-API-DMAC10.html) |
| WO (1) | WO2021097146A1 (cg-RX-API-DMAC10.html) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2024194686A2 (en) | 2023-03-17 | 2024-09-26 | Oxitope Pharma B.V. | Anti-phosphocholine antibodies and methods of use thereof |
| CN121102464B (zh) * | 2025-09-19 | 2026-08-11 | 深圳市中佳生物医疗科技有限公司 | 一种小分子调节剂通过促进epc细胞分化改善aki治疗的应用 |
Family Cites Families (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2500895A1 (en) * | 2002-10-04 | 2004-04-15 | Forskarpatent I Syd Ab | Peptide-based passive immunization therapy for treatment of atherosclerosis |
| GB0517878D0 (en) * | 2005-09-02 | 2005-10-12 | Bioinvent Int Ab | Immunotherapeutic treatment |
| JP2010510772A (ja) | 2006-11-27 | 2010-04-08 | パトリス リミテッド | 新生細胞における新規なグリコシル化ペプチド標的 |
| AU2008296487A1 (en) | 2007-08-28 | 2009-03-12 | The Uab Research Foundation | Synthetic apolipoprotein E mimicking polypeptides and methods of use |
| EP2240156A2 (en) | 2007-12-28 | 2010-10-20 | BioInvent International AB | Antibody-containing formulation for the use for treating cardiovascular diseases associated with atherosclerosis |
| US20090311271A1 (en) | 2008-05-29 | 2009-12-17 | Wyeth | Methods and Compositions for Selective Inhibition of Ligand Binding to the Lectin-Like Receptor for Oxidized Low Density Lipoprotein (LOX-1) |
| AU2010210312A1 (en) | 2009-02-09 | 2011-08-04 | Patrys Limited | SAM-6 variants, target and methods of use |
| PE20120359A1 (es) | 2009-03-06 | 2012-04-13 | Genentech Inc | Formulacion con anticuerpo |
| US8729240B2 (en) | 2010-04-28 | 2014-05-20 | National University Corporation Hokkaido University | Monoclonal antibody against oxidized low-density lipoprotein |
| WO2011160845A2 (en) * | 2010-06-24 | 2011-12-29 | Medirista Biotechnologies Ab | Oxidized phospholipids and lipoproteins, and antibodies thereto, as biomarkers of inflammatory conditions and methods of treatment |
| ES2773111T3 (es) | 2011-09-16 | 2020-07-09 | Regeneron Pharma | Inhibidor de la proproteína convertasa subtilisina/kexina 9 (PCSK9) para su uso en la reducción de los niveles de lipoproteína (a) |
| CN105358708B (zh) * | 2013-03-14 | 2024-07-16 | 儿童医学中心公司 | Cd36鉴定癌症对象以用于治疗的用途 |
| US10858422B2 (en) * | 2016-05-31 | 2020-12-08 | Abcentra, Llc | Methods for treating systemic lupus erythematosus with an anti-apolipoprotein B antibody |
| WO2017210360A1 (en) * | 2016-05-31 | 2017-12-07 | Cardiovax, Llc | Methods for diagnosing and treating systemic lupus erythematosus |
| EP3612563A1 (en) | 2017-04-19 | 2020-02-26 | Elstar Therapeutics, Inc. | Multispecific molecules and uses thereof |
| WO2019210207A2 (en) | 2018-04-27 | 2019-10-31 | The Trustees Of The University Of Pennsylvania | Chimeric antigen receptor t regulatory cells for the treatment of atherosclerosis |
| WO2019232070A1 (en) * | 2018-05-29 | 2019-12-05 | Abcentra, Llc | Compositions and methods for treatment of psoriasis |
-
2020
- 2020-11-12 JP JP2022527088A patent/JP7722989B2/ja active Active
- 2020-11-12 KR KR1020227019690A patent/KR20220131222A/ko active Pending
- 2020-11-12 US US17/776,006 patent/US12570731B2/en active Active
- 2020-11-12 CA CA3160636A patent/CA3160636A1/en active Pending
- 2020-11-12 EP EP20887856.1A patent/EP4058042A4/en active Pending
- 2020-11-12 WO PCT/US2020/060309 patent/WO2021097146A1/en not_active Ceased
- 2020-11-12 CN CN202080092637.1A patent/CN115003319B/zh active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Singh et al. | Anti-claudin 18.2 antibody as new targeted therapy for advanced gastric cancer | |
| Kunte et al. | Novel HER2–targeted therapies for HER2–positive metastatic breast cancer | |
| Esfahani et al. | A review of cancer immunotherapy: from the past, to the present, to the future | |
| JP2020011980A5 (cg-RX-API-DMAC10.html) | ||
| JP2022511394A5 (cg-RX-API-DMAC10.html) | ||
| Agustoni et al. | EGFR-directed monoclonal antibodies in combination with chemotherapy for treatment of non-small-cell lung cancer: an updated review of clinical trials and new perspectives in biomarkers analysis | |
| Li et al. | Antibody-drug conjugates in HER2-positive breast cancer | |
| Aoki et al. | Trastuzumab deruxtecan for the treatment of HER2-positive advanced gastric cancer: a clinical perspective | |
| JP2018536632A5 (ja) | Ｂ７‐ｈ３に特異的に結合する分子及びｐｄ‐１に特異的に結合する分子 | |
| JP2013520442A5 (cg-RX-API-DMAC10.html) | ||
| JP2014158469A5 (cg-RX-API-DMAC10.html) | ||
| JP2009541492A5 (cg-RX-API-DMAC10.html) | ||
| JP2016520082A5 (cg-RX-API-DMAC10.html) | ||
| JP2011505875A5 (cg-RX-API-DMAC10.html) | ||
| Qiu et al. | The progress of targeted therapy in advanced gastric cancer | |
| JP2022512713A5 (cg-RX-API-DMAC10.html) | ||
| JP2022512851A5 (cg-RX-API-DMAC10.html) | ||
| JP2022512750A5 (cg-RX-API-DMAC10.html) | ||
| JP2007515165A5 (cg-RX-API-DMAC10.html) | ||
| JP2022531408A5 (cg-RX-API-DMAC10.html) | ||
| Lindenblatt et al. | Paclitaxel improved anti-L1CAM lutetium-177 radioimmunotherapy in an ovarian cancer xenograft model | |
| Hartung et al. | Guiding TRAIL to cancer cells through Kv10. 1 potassium channel overcomes resistance to doxorubicin | |
| JPWO2022270524A5 (cg-RX-API-DMAC10.html) | ||
| JP2024515879A5 (cg-RX-API-DMAC10.html) | ||
| JP2022534808A5 (cg-RX-API-DMAC10.html) |